(Last updated : 2020-05-07 16:03:08)
  Masao Nakata
   Department     ,
   Position  
■ Present specialized field
Respiratory surgery 
■ Journal
1. 2019/12/01 Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC. 
2. 2019/11/26 Clinicopathological relevance of tumor expression of NK group 2 member D ligands in resected non-small cell lung cancer 
3. 2019/11 Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial 
4. 2019/08 Effect of platinum-based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death-1 ligand 1 and HLA class I in non-small cell lung cancer 
5. 2019/05 Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer 
Display all(76)
■ Presentation
1. 2019/09/28 JAK-STAT inhibitor overcomes interferon g-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells.  
2. 2019/04/20 Clinical effectiveness of perioperative multi-disciplinary team management for lung cancer surgery  
3. 2018/12/08 3D-complete VATS curative resection for NSCLC  
4. 2018/10/04 Analysis of intraoperative critical situations in thoracoscopic surgery for NSCLC  
5. 2018/09/25 Adjuvant chemotherapy is effective for completely resected stage IB non-small cell lung cancer  
Display all(45)